IL-1β Signalling

Interleukin-1 beta is a central pro-inflammatory cytokine in osteoarthritis, and its concentration is consistently elevated in the synovial fluid, synovial membrane and cartilage of affected joints [1]. Together with tumour necrosis factor alpha and interleukin-6, it is released in part by adipose-derived macrophages, a route that links obesity to the inflammatory burden placed on cartilage [1]. Once active, it drives chondrocytes to produce matrix metalloproteinases and aggrecanases while suppressing the synthesis of type II collagen and proteoglycan, tipping the joint toward net matrix loss [1]. It also raises intracellular reactive oxygen species and the expression of matrix-degrading proteases, so inflammation and oxidative stress reinforce one another inside the chondrocyte [2]. The signal is transmitted largely through nuclear factor kappa B, which switches on further cytokines and MMP-13 while repressing the chondrogenic transcription factor SOX9 and its target COL2A1 [3].

Mechanical overload feeds the same circuit, because abnormal loading activates interleukin-1 beta, tumour necrosis factor alpha and nuclear factor kappa B signalling in articular cartilage [4]. Sustained exposure, acting alongside p38 mitogen-activated protein kinase, pushes chondrocytes toward senescence and dedifferentiation, states in which they lose their mature phenotype and secrete still more inflammatory mediators [5]. This self-amplifying loop, in which the cytokine both degrades the matrix and reprogrammes the cells meant to maintain it, is a principal reason it is pursued as a therapeutic target [2]. Understanding how such inflammatory signals reshape the chondrocyte sits at the centre of Jessica's work on cytokine-driven cytoskeletal remodelling [3].